Literature DB >> 3492546

Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein.

M S Kaminski, K Kitamura, D G Maloney, R Levy.   

Abstract

A murine B cell lymphoma (38C13) was used as a model to study the induction of idiotype (Id)-specific tumor immunity. Immunization of syngeneic mice with Id protein derived from the tumor resulted in the production of anti-Id antibodies by the host and in the induction of a state of resistance to tumor growth. Tumor immunity could be established only if the Id protein was conjugated to a strongly immunogenic carrier protein such as keyhole limpet hemocyanin or thyroglobulin, and if the conjugate was administered at least 1 week prior to tumor challenge. Free Id protein, such as that present in tumor bearing animals, was found to inhibit tumor immunity in a dose-dependent manner. Although tumor immunity could be induced in animals with pre-existent serum Id protein, the expression of the immune state was inhibited by the presence of the soluble protein.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3492546

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.

Authors:  Stephen J Schuster; Sattva S Neelapu; Barry L Gause; John E Janik; Franco M Muggia; Jon P Gockerman; Jane N Winter; Christopher R Flowers; Daniel A Nikcevich; Eduardo M Sotomayor; Dean S McGaughey; Elaine S Jaffe; Elise A Chong; Craig W Reynolds; Donald A Berry; Carlos F Santos; Mihaela A Popa; Amy M McCord; Larry W Kwak
Journal:  J Clin Oncol       Date:  2011-05-31       Impact factor: 44.544

Review 2.  Vaccination strategies for lymphomas.

Authors:  Mohammed M Dar; Larry W Kwak
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

3.  Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines.

Authors:  Kamran Kafi; David J Betting; Reiko E Yamada; Michael Bacica; Kristopher K Steward; John M Timmerman
Journal:  Mol Immunol       Date:  2008-11-28       Impact factor: 4.407

Review 4.  Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures.

Authors:  Maurizio Bendandi
Journal:  Nat Rev Cancer       Date:  2009-09       Impact factor: 60.716

Review 5.  Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials.

Authors:  Hyun Jun Park; Sattva S Neelapu
Journal:  Br J Haematol       Date:  2008-04-13       Impact factor: 6.998

6.  Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants.

Authors:  A A McCormick; M H Kumagai; K Hanley; T H Turpen; I Hakim; L K Grill; D Tusé; S Levy; R Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

7.  Surface functionalization of virus-like particles by direct conjugation using azide-alkyne click chemistry.

Authors:  Kedar G Patel; James R Swartz
Journal:  Bioconjug Chem       Date:  2011-02-28       Impact factor: 4.774

8.  A vaccine directed to B cells and produced by cell-free protein synthesis generates potent antilymphoma immunity.

Authors:  Patrick P Ng; Ming Jia; Kedar G Patel; Joshua D Brody; James R Swartz; Shoshana Levy; Ronald Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-08       Impact factor: 11.205

Review 9.  Novel immunotherapies.

Authors:  Qing Yi
Journal:  Cancer J       Date:  2009 Nov-Dec       Impact factor: 3.360

10.  Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.

Authors:  L W Kwak; H A Young; R W Pennington; S D Weeks
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.